Overview

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6

Status:
Withdrawn
Trial end date:
2002-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in healthy, non-drug dependent volunteers.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Buprenorphine
Buprenorphine, Naloxone Drug Combination
Naloxone
Criteria
Inclusion Criteria:

Individuals must be healthy, non-drug dependent volunteers, be at least 18 years of age,
and have no prior history of drug or alcohol abuse or dependence. Subjects must have had
some minimal experience with opioids (e.g. at least two prior exposures)

Exclusion Criteria:

Individuals with evidence of an active Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness,
organic psychiatric disorders), significant medical illness (e.g., liver or cardiovascular
disease) or pregnant female subjects are excluded from study participation.